Company Profile · Healthcare

Absci Corp

ABSI · US
Industry
AI Pharmaceuticals (AI Drug Discovery)
Exchange
US
Country
USA
IPO date
Jul 22, 2021
Employees
140
Website
www.absci.com
Current Price
$9.76
Live · Jul 16, 2026
Fair Buy
≤ $5
Margin-of-safety entry
Baillie Growth Score
35/100
Weak
Intrinsic Value · Three-Tier Range Current price $9.76 Live · Between the fair and optimistic ranges

Composite valuation range · conservative $3.8–$5 / fair $6.5–$8.5 / optimistic $12.5–$14.5. At $9.76, Between the fair and optimistic ranges.

At publication $7.56 (Jul 25, 2026)

Financial snapshot
Market cap$1.38B
Revenue (TTM)$1.84M
EBITDA-$116.44M
Profit margin0%
ROE-63.89%
Forward P/E0
EPS-$0.82
52-week range$2.24 – $12.06
Analyst target$13.78
Analyst rating4.6 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
35/100 Hold Absci Corporation: The Platform Is Real, but the Price Already Bets Big on ABS-201 Absci is a clinical-stage biotech that uses generative AI, proprietary high-throughput lab data, and wet-lab validation cycles to design antibodies, but current revenue still comes almost entirely from small, lumpy partnered discovery fees rather than owned products. FY2025 revenue was just $2.8 million and fell further to $0.2 million in Q1 2026, while the June 2026 announcement of positive interim Phase 1 safety data for lead asset ABS-201 (androgenetic alopecia) let the company raise $100 million, including a $40 million allocation from Eli Lilly, at $7.41 a share. Rating Hold: the platform and early clinical data are genuinely more credible than a year ago, but at $7.56 the stock already sits near a roughly $1.2-1.3 billion valuation on almost no current revenue, leaving little room for anything short of a strong ABS-201 efficacy readout. Absci CorporationABSI · USAI Pharmaceuticals (AI Drug Discovery)Jul 25, 2026